GASR: The Global Angelman Syndrome Registry

Sponsor
Foundation for Angelman Syndrome Therapeutics, Australia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05293184
Collaborator
Queensland University of Technology (Other)
2,000
1
999.1
2

Study Details

Study Description

Brief Summary

The Global Angelman Syndrome Registry is an online patient organisation driven registry to collect information about the natural history of children and adults with Angelman Syndrome. The registry will facilitate 1) recruitment for clinical trials into therapies and interventions to benefit participants with Angelman Syndrome and their families, and 2) advancement of research and best standards of care for Angelman Syndrome.

The registry is currently available in English, Spanish, Traditional Chinese and Italian.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational study only

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
2000 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
The Global Angelman Syndrome Registry
Actual Study Start Date :
Sep 28, 2016
Anticipated Primary Completion Date :
Dec 31, 2099
Anticipated Study Completion Date :
Dec 31, 2099

Arms and Interventions

Arm Intervention/Treatment
Individuals with Angelman Syndrome

Individuals from birth to adulthood with Angelman Syndrome

Other: Observational study only

Outcome Measures

Primary Outcome Measures

  1. Gather longitudinal data on individuals living with Angelman Syndrome [70 years (lifespan)]

    Parent/ caregiver reporting on diagnosis, clinical status, and patient-reported outcomes of individual living with Angelman Syndrome. This will be achieved by inviting parents/ caregivers with additional questionnaire like modules, and tracking changes in their responses over time.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Angelman Syndrome
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Queensland University of Technology Brisbane Queensland Australia 4000

Sponsors and Collaborators

  • Foundation for Angelman Syndrome Therapeutics, Australia
  • Queensland University of Technology

Investigators

  • Principal Investigator: Helen (Honey) Heussler, MBBS, FRACP DM, The University of Queensland

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Associate Professor Helen (Honey) Heussler, Associate Professor, Paediatrics and Child Health, The University of Queensland
ClinicalTrials.gov Identifier:
NCT05293184
Other Study ID Numbers:
  • RG-16-078-AM01
First Posted:
Mar 24, 2022
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Associate Professor Helen (Honey) Heussler, Associate Professor, Paediatrics and Child Health, The University of Queensland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022